top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 2 days ago
  • 1 min read

27/02/2026


























Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata (Ref)


Eli Lilly and Company and Incyte announced European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for Olumiant (baricitinib; JAK inhibitor) for the treatment of adolescent patients aged 12 to 18 with severe alopecia areata (AA)


  • The positive opinion was based on data from the Phase 3/ BRAVE-AA-PEDS/  study, in which 42% of patients with severe AA had reached 80% or more scalp hair coverage at 36 weeks


  • The safety profile of Olumiant in adolescents with AA was consistent with that seen in trials for children with juvenile idiopathic arthritis and moderate-to-severe atopic dermatitis


  • Lilly had submitted Olumiant in the US for approval to treat severe AA in adolescents, with a decision expected in H2 2026




bottom of page